AI-generated research brief — verify at source
Adding Cefixime to Azithromycin Shows No Benefit in Uncomplicated Typhoid Fever
In a large phase 4 randomised controlled trial across three South Asian countries, combining cefixime with azithromycin produced identical treatment failure rates to azithromycin alone — 5.1% in each group — with an absolute risk difference of essentially zero (absolute risk difference −0.00 percentage points, 95% CI −2.08 to 2.08; p=1.00). The finding is robustly null, with confidence intervals narrow enough to rule out any clinically meaningful benefit from the combination.
What Was Studied
This trial investigated whether adding cefixime — an oral third-generation cephalosporin with extracellular bactericidal activity — to the WHO-recommended azithromycin could reduce treatment failure in uncomplicated typhoid fever. The rationale was pharmacokinetic complementarity: azithromycin acts intracellularly while cefixime targets extracellular bacteria, and both drugs individually carry reported failure rates of 10% or higher. The primary outcome was a composite measure of treatment failure within 28 days, incorporating fever clearance time of seven days or more, microbiological failure at day 7, need for rescue treatment, or typhoid-related complication or relapse.
How It Was Studied
This was a double-blind, placebo-controlled, parallel-group, phase 4 randomised trial enrolling adults and children aged 2–65 years presenting with acute undifferentiated febrile illness at outpatient and emergency clinics in Nepal, Bangladesh, and Pakistan. Eligible participants had fever lasting 3–14 days, a C-reactive protein of at least 10 mg/L, and negative screening for dengue, scrub typhus, malaria, and COVID-19; cases were either blood culture-confirmed or clinically suspected typhoid. A total of 1,831 participants comprised the modified intention-to-treat population, randomised 1:1 using computer-generated block randomisation stratified by site and age. The intervention arm received oral azithromycin (20 mg/kg once daily, maximum 1 g) plus cefixime (10 mg/kg twice daily, maximum 400 mg) for seven days; the comparator arm received the same azithromycin regimen plus matched placebo. Enrolment ran from May 2021 to September 2025, with follow-up to 28 days post-treatment.
What Was Observed
- No difference in the primary composite endpoint: Treatment failure occurred in exactly 44 participants (5.1%) in each arm — an absolute risk difference of zero (95% CI −2.08 to 2.08; p=1.00). The confidence interval is narrow, providing strong evidence against a meaningful treatment effect from adding cefixime.
- Numerically higher failure in culture-confirmed cases receiving monotherapy, but not statistically significant: Among the 350 blood culture-confirmed participants, 11.2% (19/179) in the combination arm failed treatment versus 16.0% (26/171) in the azithromycin-only arm — a difference of 4.48 percentage points that did not reach statistical significance (95% CI −2.52 to 12.21; p=0.20), and this subgroup was insufficiently powered to draw firm conclusions.
- Adverse event profiles were equivalent across both arms: Adverse events were reported in 16% of participants in each group (142 in the combination arm, 144 in the monotherapy arm). Serious adverse events requiring hospitalisation occurred in 21 participants (2%) on combination therapy and 17 (2%) on monotherapy — no meaningful safety difference.
Why This Matters
WHO already recommends azithromycin monotherapy for uncomplicated typhoid fever, but the use of cefixime — alone or in combination — remains widespread in clinical practice across typhoid-endemic settings. This trial provides direct evidence that the pharmacokinetic rationale for combining these two agents does not translate into improved clinical outcomes. The authors conclude this supports adherence to azithromycin monotherapy and has concrete implications for antimicrobial stewardship programs in the region, where unnecessary combination antibiotic use carries risks for resistance development and healthcare costs.
How to Read This Result
This is a high-quality, adequately powered, double-blind phase 4 trial with a precisely estimated null result, though the numerically lower failure rate in culture-confirmed patients on combination therapy warrants cautious attention, as the culture-confirmed subgroup was too small to exclude a modest benefit in that specific population.
Limitations
Enrollment of both culture-confirmed and clinically suspected cases introduces diagnostic heterogeneity that may dilute treatment effects in the overall population; a substantial proportion of participants may not have had true typhoid fever. The culture-confirmed subgroup, where failure rates were higher and the numeric difference between arms was largest, was underpowered to detect a statistically or clinically meaningful difference, leaving uncertainty about combination therapy’s potential role in bacteraemic disease specifically. Reliance on clinical suspicion for the majority of enrolled cases represents an inherent limitation in pragmatic trial settings where blood culture sensitivity is imperfect.